In Maryland, LifeMark Partners, Inc., an independent national insurance marketing organization, announced that a complimentary cancer genomic profiling program will be exclusively available to its partner BGAs. This first of its kind offer will allow BGAs affiliated with LifeMark Partners to initially provide 250,000 Americans, who purchased new life insurance policies, with instant complimentary access for one year to Wamberg Genomic Advisors’ Cancer Guardian program. Cancer Guardian is for the sequencing of a cancer tumor to learn about coding mutations that contribute to tumor progression.
The information provided by Wamberg Genomic Advisors Cancer Guardian program can be used to increase the accuracy of the diagnosis and highlight more effective and appropriate treatment options, including clinical trials, based on the genetic profile of an individual’s cancer. The 2017 MOSCATO trial showed that half of cancers have actionable genetic mutations that are potentially treatable with targeted cancer drugs that currently exist. When obtaining these comprehensive genomic tests outside of Wamberg Genomic Advisors’ innovative program, the prices in excess of $7,000 and are not covered by health insurance in most cases.